TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Bronstein, Gewirtz & Grossman Llc
SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Skye Bioscience, Inc. for alleged securities fraud. The complaint alleges that defendants made materially false and misleading statements regarding nimacimab's effectiveness and commercial prospects during the period from November 4, 2024 to October 3, 2025. Investors with substantial losses are encouraged to participate, with a lead plaintiff deadline of January 16, 2026.

Insights
SLXNW   positive

Demonstrated positive preclinical data across multiple cancer types, successfully raised capital, regained Nasdaq listing compliance, and maintained clear progress toward clinical trial initiation


SKYE   negative

The company is the subject of a securities fraud class action lawsuit alleging materially false and misleading statements about its drug candidate nimacimab's effectiveness and commercial prospects, resulting in investor losses.